This is an extract taken from the companies website for those of you having trouble with the link, there is more available on the LCT website..... roll on 2017:)))
LCT starts Phase IIb clinical trial of NTCELL for Parkinson’s disease
24 March 2016 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies has
received approval from the Auckland Hospital Research Review Committee for the Phase IIb clinical
trial of NTCELL® for Parkinson’s disease. The New Zealand Minister of Health authorised the
application to conduct the trial on 12 November 2015, and the Northern A Health and Disability Ethics
Committee gave its approval on 3 February 2016. The initiation meeting with all those involved in the
clinical trial has been held and patient recruitment is under way.
The Phase IIb trial follows the successful Phase I/IIa trial, which met the primary endpoint of safety
and showed clinically and statistically significant efficacy data in patients with Parkinson’s disease one
year after NTCELL treatment.
The Phase IIb trial aims to confirm the most effective dose of NTCELL, define any placebo component
of the response and further identify the initial target Parkinson’s disease patient sub group.
If the trial is successful the company will apply for provisional consent to treat paying patients in New
Zealand and launch NTCELL as the first disease modifying treatment for Parkinson’s disease, in 2017.